طريقة تسجيل في دراسه لطفلي
A Phase 2 interventional study of KER-065 in Duchenne Muscular Dystrophy, sponsored by Keros Therapeutics, Inc.. Recruiting at 4 sites in 2 countries. Open to male participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Keros Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KER-065 administered to adult and pediatric ambulatory and nonambulatory male participants with Duchenne Muscular Dystrophy (DMD) on stable background therapy.
This is a Phase 2, multicenter, open-label study of KER-065.
The study will consist of 3 periods:
Participants will be enrolled in parallel into 1 of 3 treatment cohorts:
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
This study's planned enrollment of 36 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Browse Muscular Dystrophy, Duchenne studies →Keros Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Ambulatory Participants Only (Cohort A1 and A2):
Nonambulatory Participants Only (Cohort N1):
Key Exclusion Criteria:
Nonambulatory Participants Only (Cohort N1):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive stable corticosteroid (CS) along with KER-065.
Drug: KER-065
Participants will receive stable CS, exon skipper along with KER-065.
Drug: KER-065
Participants will receive stable CS along with KER-065.
Drug: KER-065
KER-065 will be administered subcutaneously (SC)
Also known as: Rinvatercept
Number of participants with treatment-emergent adverse events (TEAEs and serious adverse events (SAEs)
To evaluate the safety and tolerability of KER-065 in ambulatory and nonambulatory participants with DMD
Time frame: Up to approximately 14 months
KER-065 serum concentration by visit, as appropriate
To assess the pharmacokinetics (PK) of KER-065 in ambulatory and nonambulatory participants with DMD
Time frame: Up to Week 52
Number and proportion of participants with treatment-emergent ADA (antidrug antibody) by visit
To assess the immunogenicity of KER-065 in ambulatory and nonambulatory participants with DMD
Time frame: Up to Week 52
Change from baseline by visit in bone mineral density (BMD), fat mass, and lean body mass, as measured by dual- energy X-ray absorptiometry (DXA)
To assess the effect of KER-065 on body composition in ambulatory and nonambulatory participants with DMD
Time frame: Week 12, Week 24 and Week 48
Change from baseline by visit in muscle volume and intramuscular fat by skeletal muscle Magnetic Resonance Imaging (MRI)
To assess the effect of KER-065 on skeletal muscle in ambulatory and nonambulatory participants with DMD
Time frame: Week 24 and Week 48
Ambulatory: Change from baseline by visit in North Star Ambulatory Assessment (NSAA) total score
To assess the effect of KER-065 on motor function in ambulatory participants with DMD
Time frame: Week 24 and Week 48
Ambulatory: Change from baseline by visit in 4-stair climb (4SC)
To assess the effect of KER-065 on motor function in ambulatory participants with DMD
Time frame: Week 24 and Week 48
Ambulatory: Change from baseline by visit in 10-meter walk/run (10MWR) test
To assess the effect of KER-065 on motor function in ambulatory participants with DMD
Time frame: Week 24 and Week 48
Ambulatory: Change from baseline by visit in time to rise (TTR)
To assess the effect of KER-065 on motor function in ambulatory participants with DMD
Time frame: Week 24 and Week 48
Nonambulatory: Change from baseline by visit in Performance of Upper Limb (PUL) v2.0 score
To assess the effect of KER-065 on motor function in nonambulatory participants with DMD
Time frame: Week 24 and Week 48
Started Sep 2026 (actual). Primary completion is estimated for Aug 2028, 23 months after the start.
Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 23 months is below that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jul 2029 → Aug 2028 and completion Aug 2029 → Sep 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
طريقة تسجيل في دراسه لطفلي
Muscular Dystrophy, Duchenne →
Keros Therapeutics, Inc.